Pulse Biosciences, Inc.
PLSE•NASDAQ•Healthcare•Medical Instruments & Supplies

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.pulsebiosciences.com
Phone510 906 4600
Address
601 Brickell Key Drive, Suite 1080 Miami, Florida 33131 United States

Corporate Identifiers

CIK0001625101
CUSIP74587B101
ISINUS74587B1017
EIN46-5696597
SIC3841

Leadership Team & Key Executives

Paul Arthur LaViolette
President, Chief Executive Officer and Co-Chairman of the Board
Darrin R. Uecker
Chief Technology Officer and Director
Kevin P. Danahy
Chief Commercial Officer
Jon Skinner
Chief Financial Officer
Edison Manuel
Vice President of Operations
Steven T. Weber
Vice President of Accounting, Principal Accounting Officer and Global Corporate Controller
Kenneth B. Stratton Esq., J.D.
General Counsel and Corporate Secretary
Patty Perla
Vice President of Human Resources
Mitchell E. Levinson
Chief Strategy Officer
David Danitz
Senior Vice President of Engineering